PubMed:11201732 / 559-700 JSONTXT

{"project":"2015-BEL-Sample","denotations":[{"id":"T1","span":{"begin":0,"end":141},"obj":"a(CHEBI:rosiglitazone) decreases sec(p(MGI:Retn))"}],"text":"Circulating resistin levels are decreased by the anti-diabetic drug rosiglitazone, and increased in diet-induced and genetic forms of obesity"}

{"project":"2015-BEL-Sample-2","denotations":[{"id":"BEL:20000264","span":{"begin":0,"end":141},"obj":"path(MESHD:Obesity) increases sec(p(MGI:Retn))"},{"id":"BEL:20000266","span":{"begin":0,"end":141},"obj":"a(CHEBI:rosiglitazone) decreases sec(p(MGI:Retn))"}],"text":"Circulating resistin levels are decreased by the anti-diabetic drug rosiglitazone, and increased in diet-induced and genetic forms of obesity"}